Slone Partners Recruits Chief Scientific Officer for Prolynx
July 20, 2026 – Life sciences-focused search firm Slone Partners has recruited Amer Mirza as chief scientific officer at Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions.
“Dr. Amer Mirza is an accomplished scientific leader whose deep expertise in drug discovery and development and passion for innovation make him exceptionally well suited to serve as chief scientific officer at Prolynx,” Leslie Loveless, managing partner and CEO at Slone Partners. “His ability to translate groundbreaking science into meaningful clinical progress will be invaluable for the company,” said “We are proud to have partnered with Prolynx on this important search and look forward to seeing the impact Amer will have on the company’s continued success.”
“We believe long-acting agents with the potential to be dosed on a monthly or quarterly basis represent one of the most important next frontiers for the long-term management of people living with obesity and related conditions,” said Chris Boulton, CEO of Prolynx. “The opportunity for Prolynx is to turn its proprietary half-life-extension platform into a pipeline of medicines that can meaningfully change long-term treatment for patients. With our expanded leadership team and the proven track records they bring across R&D, development and company-building, we have the expertise needed to advance multiple programs toward the clinic and deliver on our ambition to bring transformative medicines to patients in need.”
In his position, Dr. Mirza will help drive R&D execution as Prolynx advances its ultra-long-acting portfolio for obesity and related metabolic diseases. He brings nearly 25 years of drug discovery and development experience, with particular expertise in metabolic disease, translational science, and preclinical pharmacology, and a track record of moving programs through IND-enabling studies. Most recently, Dr. Mirza served as vice president of disease biology and translational sciences at Septerna, and previously held senior R&D and translational leadership roles at Ascendis Pharma, Gilead Sciences, and XOMA.
“With its proprietary modular platform, Prolynx has built a compelling scientific foundation for ultra-long-acting medicines engineered to overcome the challenges around chronic treatment,” said Dr. Mirza. “By aiming to improve tolerability, reduce treatment burden, and support more durable care, this portfolio has the potential to address limitations that continue to shape current treatments for obesity and related metabolic diseases. I look forward to accelerating these programs toward clinical milestones to deliver transformative therapies for patients who may benefit from new long-term treatment options.”
Related: Slone Partners Recruits CEO for Syra Health
Prolynx is a biotechnology company dedicated to developing ultra-long-acting medicines for obesity and other metabolic diseases. The company is advancing a proprietary portfolio of extended-duration therapeutic candidates, targeting once-monthly and once-quarterly dosing, optimized to smooth the peaks and troughs that can contribute to tolerability issues and to support more consistent, long-term treatment. Backed by 5AM Ventures, OrbiMed, and Monograph Capital, Prolynx is based in Emeryville, CA.
Nationally Recognized
Slone Partners is a nationally recognized senior-level recruitment provider that specializes in delivering executive, management, and leadership talent for the diagnostic, biopharmaceutical, healthcare information technology, and laboratory testing industries. The firm has offices in Boston, New York, Washington, D.C., and San Francisco. Recently, Slone Partners was included among Hunt Scanlon Media’s “Top 50 Healthcare & Life Sciences Search Firms.”
In 2000, Adam Slone founded Slone Partners and acted as CEO from 2000 to 2016. He remains chairman today. His industry knowledge and extensive contacts have enabled Slone Partners to place thousands of executives and industry professionals. Today, Mr. Slone remains engaged with Slone Partners, with a specific focus in strategy, finance, M&A advisement, and business development in Boston and California.
Ms. Loveless has nearly 20 years of healthcare industry and executive search experience to Slone Partners. She joined the firm in 2007, became COO in 2014 and CEO in 2016. At Slone Partners, Ms. Loveless acts as the leader of the organization as well as the head of the executive search team. Her involvement with clients and candidates enables her to understand the key motivations of each. As CEO, Ms. Loveless’ focus extends to cultivating new business partnerships and expanding relationships with existing clients. Through her leadership, life sciences and biotechnology have emerged as the primary client base for Slone Partners.
Related: Slone Partners Recruits Chief Business Officer for Vertero Therapeutics
Contributed by Scott A. Scanlon, Editor-in-Chief and Dale M. Zupsansky, Executive Editor – Hunt Scanlon Media
